Please note, this OEL/ADE monograph also applies to plerixafor hydrochloride (CAS RN 155148-31-5). Plerixafor is indicated for the harvesting of peripheral blood stem cells for patients with non- Hodgkin lymphoma (blood cancer) and multiple myeloma (cancer of plasma cells). Plerixafor is a hematopoietic stem cell mobilizer which inhibits the CXCR4 chemokine receptor and blocks binding of its ligand, stromal cell-derived factor-1-alpha (SDF-1-alpha) which results in increased white blood cells and elevations in circulating stem cells.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Plerixafor, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.